Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors.

CTLA-4 HLA NMDAR PD-1 autoimmune encephalitis immune checkpoint inhibitors neurological adverse events paraneoplastic neurological syndromes

Journal

Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242

Informations de publication

Date de publication:
2020
Historique:
received: 11 04 2020
accepted: 17 05 2020
entrez: 9 7 2020
pubmed: 9 7 2020
medline: 9 7 2020
Statut: epublish

Résumé

Paraneoplastic neurological syndromes (PNSs) are rare complications of systemic cancers that can affect all parts of the central and/or peripheral nervous system. A body of experimental and clinical data has demonstrated that the pathogenesis of PNSs is immune-mediated. Nevertheless, the mechanisms leading to immune tolerance breakdown in these conditions remain to be elucidated. Despite their rarity, PNSs offer a unique perspective to understand the complex interplay between cancer immunity, effect of immune checkpoint inhibitors (ICIs), and mechanisms underlying the attack of neurons in antibody-mediated neurological disorders, with potentially relevant therapeutic implications. In particular, it is reported that ICI treatment can unleash PNSs and that the immunopathological features of PNS-related tumors are distinctive, showing prominent tumor-infiltrating lymphocytes and germinal center reactions. Intriguingly, similar pathological substrates have gained further attention as potential biomarkers of ICI-sensitivity and oncological prognosis. Moreover, the genetic analysis of PNS-associated tumors has revealed specific molecular signatures and mutations in genes encoding onconeural proteins, leading to the production of highly immunogenic neoantigens. Other than PNSs, autoimmune encephalitides (AEs) comprise a recently described group of disorders characterized by prominent neuropsychiatric symptoms, diverse antibody spectrum, and less tight association with cancer. Other triggering factors seem to be involved in AEs. Recent data have shed light on the importance of preceding infections (in particular, herpes simplex virus encephalitis) in inducing neurological autoimmune disorders in susceptible individuals (those with a selective deficiency in the innate immune system). In addition, in some AEs (e.g. LGI1-antibody encephalitis) an association with specific host-related factors [e.g., human leukocyte antigen (HLA)] was clearly demonstrated. We provide herein a comprehensive review of the most recent findings in the field of PNSs and AEs, with particular focus on their triggering factors and immunopathogenesis.

Identifiants

pubmed: 32636932
doi: 10.1177/1756286420932797
pii: 10.1177_1756286420932797
pmc: PMC7318829
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1756286420932797

Informations de copyright

© The Author(s), 2020.

Déclaration de conflit d'intérêts

Conflict of interest statement: AV reported receiving a fellowship grant from the European Academy of Neurology (EAN). No other disclosures were reported.

Références

Semin Neurol. 2019 Apr;39(2):283-292
pubmed: 30925620
JAMA Neurol. 2014 Jun;71(6):717-24
pubmed: 24781184
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Acta Neuropathol Commun. 2019 Mar 11;7(1):38
pubmed: 30857565
Nat Rev Neurol. 2017 Dec;13(12):755-763
pubmed: 29104289
Br J Cancer. 2018 Jul;119(1):105-113
pubmed: 29899393
Ann Neurol. 2018 Mar;83(3):553-561
pubmed: 29406578
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40
pubmed: 15258215
Brain. 2003 Jun;126(Pt 6):1409-18
pubmed: 12764061
J Clin Invest. 2009 Jul;119(7):2042-51
pubmed: 19509467
Lancet. 1999 Jan 9;353(9147):117-8
pubmed: 10023900
J Neurol. 2020 May;267(5):1348-1352
pubmed: 31960135
Eur J Neurol. 2011 Jan;18(1):19-e3
pubmed: 20880069
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3):
pubmed: 32170044
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Neurology. 2011 Jun 14;76(24):2089-95
pubmed: 21670438
Nat Rev Neurol. 2017 May;13(5):290-301
pubmed: 28418022
Neurol Neuroimmunol Neuroinflamm. 2017 Dec 05;5(1):e416
pubmed: 29379821
Rev Neurol (Paris). 2019 Sep - Oct;175(7-8):420-426
pubmed: 31371185
J Neuroimmunol. 2019 Sep 15;334:576980
pubmed: 31195181
Neurology. 2017 May 2;88(18):1736-1743
pubmed: 28381508
J Immunother Cancer. 2019 May 22;7(1):134
pubmed: 31118078
Brain. 2018 Aug 1;141(8):2263-2271
pubmed: 29788256
J Neurol. 2020 Jul;267(7):1906-1911
pubmed: 32152690
Neurology. 2017 Oct 3;89(14):1471-1475
pubmed: 28878050
Arch Neurol. 2010 Sep;67(9):1109-15
pubmed: 20837856
J Neuroimmunol. 2019 May 15;330:136-142
pubmed: 30878696
J Neurol Sci. 2004 Jan 15;217(1):25-30
pubmed: 14675605
Eur J Cancer. 2017 Mar;73:1-8
pubmed: 28064139
Neurol Neuroimmunol Neuroinflamm. 2019 Aug 12;6(6):
pubmed: 31454761
Auto Immun Highlights. 2020 Jan 22;11(1):2
pubmed: 32127039
Lancet Neurol. 2020 Mar;19(3):234-246
pubmed: 32057303
PLoS One. 2019 Jan 29;14(1):e0211358
pubmed: 30695048
Neurol Neuroimmunol Neuroinflamm. 2018 Dec 26;6(2):e529
pubmed: 30697582
Brain Dev. 2018 Jun;40(6):473-479
pubmed: 29599011
J Autoimmun. 2019 Nov;104:102339
pubmed: 31611142
Arch Neurol. 2010 Mar;67(3):330-5
pubmed: 20212230
J Neuroimmunol. 2018 Feb 15;315:28-32
pubmed: 29306402
Neuro Oncol. 2012 Apr;14(4):506-10
pubmed: 22351748
J Neurol. 2019 Feb;266(2):398-410
pubmed: 30498914
J Neurol. 2021 May;268(5):1689-1707
pubmed: 31655889
Semin Diagn Pathol. 2019 Jul;36(4):279-292
pubmed: 31253539
Mayo Clin Proc. 2019 Sep;94(9):1865-1878
pubmed: 31358366
Leukemia. 2019 Jan;33(1):132-147
pubmed: 29946193
Nat Med. 2019 Aug;25(8):1243-1250
pubmed: 31332390
Expert Opin Drug Saf. 2020 Apr;19(4):479-488
pubmed: 32126176
Physiol Rev. 2017 Apr;97(2):839-887
pubmed: 28298428
Ann Neurol. 2018 Apr;83(4):863-869
pubmed: 29572931
J Neurol. 2018 Mar;265(3):669-677
pubmed: 29383516
Brain. 2012 May;135(Pt 5):1622-38
pubmed: 22539258
Lancet Neurol. 2018 Sep;17(9):760-772
pubmed: 30049614
Neurology. 2016 Oct 4;87(14):1449-1456
pubmed: 27590293
Ann Neurol. 2020 May;87(5):659-669
pubmed: 32086972
JAMA Neurol. 2013 Oct;70(10):1305-10
pubmed: 23939463
JAMA Neurol. 2020 Feb 1;77(2):255-256
pubmed: 31860013
Neurology. 2014 Nov 18;83(21):1888-97
pubmed: 25339207
Epilepsia. 2019 Aug;60(8):1508-1525
pubmed: 31283859
Lancet Neurol. 2011 Jan;10(1):63-74
pubmed: 21163445
Oncoimmunology. 2013 Dec 1;2(12):e27384
pubmed: 24501693
JAMA Neurol. 2016 Aug 1;73(8):928-33
pubmed: 27271951
Ann Neurol. 2017 Feb;81(2):193-198
pubmed: 28026046
J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):652-658
pubmed: 30636700
Orphanet J Rare Dis. 2007 May 04;2:22
pubmed: 17480225
Cerebellum. 2019 Oct;18(5):976-982
pubmed: 31463826
JAMA Neurol. 2016 Sep 1;73(9):1115-24
pubmed: 27428927
Acta Neuropathol. 2011 Oct;122(4):381-400
pubmed: 21938556
Brain. 2019 Jun 1;142(6):1631-1643
pubmed: 31009048
J Clin Oncol. 2008 Sep 10;26(26):4276-81
pubmed: 18779614
Ann Neurol. 2017 Feb;81(2):183-192
pubmed: 28026029
Neurol Neuroimmunol Neuroinflamm. 2019 Aug 7;6(6):
pubmed: 31454760
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3):
pubmed: 32170042
Neurology. 2007 Mar 20;68(12):900-5
pubmed: 17151337
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
J Neurooncol. 2019 Jan;141(2):431-439
pubmed: 30607708
Ther Adv Neurol Disord. 2018 Apr 23;11:1756286418768778
pubmed: 29774053
J Neuroimmunol. 2020 Apr 15;341:577184
pubmed: 32058173
Cerebellum. 2019 Apr;18(2):245-254
pubmed: 30350014
Sci Transl Med. 2014 Apr 2;6(230):230ra45
pubmed: 24695685
Neurology. 2000 Nov 28;55(10):1531-5
pubmed: 11094109
Lancet Psychiatry. 2020 Jan;7(1):93-108
pubmed: 31669058
Ann Rheum Dis. 2019 Jan;78(1):150-152
pubmed: 30185415
Handb Clin Neurol. 2016;133:107-20
pubmed: 27112674
J Neuroimmunol. 2010 Sep 14;226(1-2):147-9
pubmed: 20547426
Brain. 2004 Aug;127(Pt 8):1831-44
pubmed: 15215214
J Clin Endocrinol Metab. 1993 Dec;77(6):1550-3
pubmed: 8263140
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii59-vii67
pubmed: 31816080
Acta Neuropathol. 2018 Apr;135(4):569-579
pubmed: 29299667
N Engl J Med. 2003 Oct 16;349(16):1543-54
pubmed: 14561798
Nat Rev Clin Oncol. 2019 Sep;16(9):535-548
pubmed: 30867573
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Nat Med. 1998 Nov;4(11):1321-4
pubmed: 9809559
J Neurol Sci. 2015 Mar 15;350(1-2):105-6
pubmed: 25661887
N Engl J Med. 2019 Jul 4;381(1):47-54
pubmed: 31269365
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
J Immunother Cancer. 2019 Dec 3;7(1):337
pubmed: 31796119
Neurology. 2017 Sep 12;89(11):1127-1134
pubmed: 28821685
Ann Neurol. 2018 Jan;83(1):166-177
pubmed: 29293273
J Neurol. 2020 Jan;267(1):26-35
pubmed: 31552550
Eur J Neurosci. 2016 Jun;43(12):1535-52
pubmed: 26918657
Brain. 2016 Nov 1;139(11):2923-2934
pubmed: 27604307
Neurol Neuroimmunol Neuroinflamm. 2020 Jan 17;7(2):
pubmed: 31953309

Auteurs

Alberto Vogrig (A)

French Reference Center for Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France.

Sergio Muñiz-Castrillo (S)

French Reference Center for Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France.

Virginie Desestret (V)

French Reference Center for Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France.

Bastien Joubert (B)

French Reference Center for Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon, France.

Jérôme Honnorat (J)

Centre de Référence National pour les Syndromes Neurologiques Paranéoplasiques, Hôpital Neurologique, 59 Boulevard Pinel, Bron Cedex, 69677, France.

Classifications MeSH